IntraBio Wins Priority Voucher for Aqneursa Approval
Federal Register notice: FDA is announcing that it issued IntraBio a priority review voucher after determining its recent approval of Aqneursa (levacetylleucine), indicated for treating Niemann-Pick disease Type C in adults and pediatric patients, met the voucher criteria for issuance. To view the notice, click here.